Cell reports. MedicineInterleukin-10AnimalsProgrammed Cell Death 1 ReceptorMiceHumans
An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery.
Ce Gu, Jian Guo, Chang Zhou, Peipei Hu, Xiaodong Wu, Jiaojiao Ding, Xinxin Zhou, Liao Zeng, Wen Yu, Yingye Ou, Linhui Ye, Mengying Liang, Yue Huang, Jiatian Li, Zhe Zhang
Published: 202610.1016/j.xcrm.2025.102515
Abstract
Immune checkpoint blockade (ICB) therapy exerts anti-tumor efficacy mainly by activating intratumoral CD8+ T cells but fails to re-activate terminally exhausted CD8+ T cells. Interleukin-10 (IL-10) has been shown to directly expand and activate these…
Preview only. Read the full abstract at the source